Medilec Ltd

Predicting Sudden Cardiac Death (SCD) Medilec Ltd is a UK medical product company that is developing cardiac electrophysiology (EP) analysis instrumentation for the prediction of levels of risk of sudden cardiac death (SCD) — a major cause of death. This condition is also known as Sudden Adult Death Syndrome (SADS). Medilec's innovative EP cardiac technology, benefits from extensive published academic clinical research, and derives from British Heart Foundation (BHF) funded research at St George's Hospital, London. This was then followed by commercial research conducted in collaboration with Papworth Hospital and the University of Cambridge. The cardiac technology has benefited from a number of development stages, some of which have been funded by the British Heart Foundation (BHF) and the UK Department for Health MedLINK programme. Shareholders in Medilec include Dr Keith Barfoot, Papworth Hospital NHS Trust and the University of Cambridge. Medilec is now seeking a commercial partner and /or collaborators to help bring the technology to market.
Social Link - Linkedin: http://www. linkedin.com/company /medilec-ltd
Employee Count: 1
Keywords: hospital & health care